Evidence-based phytoiatry, a new approach in crop protection by M. Iriti & E.M. Varoni
 International Journal of 
Molecular Sciences
Editorial
Evidence-Based Phytoiatry, a New Approach in
Crop Protection
Marcello Iriti 1,* and Elena Maria Varoni 2
1 Dipartimento di Scienze Agrarie e Ambientali, Università degli Studi di Milano, via G. Celoria 2,
20133 Milan, Italy
2 Dipartimento di Scienze Biomediche, Chirurgiche e Odontoiatriche, Università degli Studi di Milano,
via Beldiletto 1/3, 20142 Milan, Italy; elena.varoni@unimi.it
* Correspondence: marcello.iriti@unimi.it; Tel.: +39-02-50316766
Received: 29 December 2018; Accepted: 3 January 2019; Published: 5 January 2019


Abstract: In the past decades, the scientific quality of biomedical studies has been hierarchically
depicted in the well-known pyramid of evidence-based medicine (EBM), with higher and higher
levels of evidence moving from the base to the top. Such an approach is missing in the modern
crop protection and, therefore, we introduce, for the first time, this novel concept of evidence-based
phytoiatry in this field. This editorial is not a guideline on plant protection products (PPP) registration,
but rather a scientific and technical support for researchers involved in the general area of plant
pathology, providing them with evidence-based information useful to design critically new studies.
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The term “evidence-based medicine” (EBM) was first introduced in 1992 in the Journal of American
Medical Association (JAMA), referring to the use and the critical appraisal of the best scientific evidence
to support clinical decision-making. This idea purported that all medical activities intended for
diagnosis, prognosis and therapy should be based, not primarily on clinical experiences, but on solid
scientific evidences coming from clinical research. Since then, EBM approach has continued to grow
and spread, taking a pivotal place beside the competence of the clinician and the care preferences of
the single patient.
This new way of thinking and acting now accounts the most updated evidence resulting from
methodologically rigorous studies, mainly randomized controlled clinical trials (RCTs) and systematic
reviews, which correspond to the highest level of scientific quality and represent the top of the EBM
pyramid (Figure 1). The base consists of pre-clinical research (in vitro and in vivo experiments),
expert opinions and case reports/series, while the middle part is composed of observational studies
including case-control and cohort studies, and RCTs and systematic reviews constitute the top.
RCTs are intervention studies considered the gold standard of clinical research to evaluate the
efficacy/effectiveness of a therapy, because of their ability to minimize the biases over other types
of clinical trials [1]. The cornerstone of RCT is randomization, which allows distributing each
prognostic factor homogeneously between the test group and the control group. The tip of the pyramid,
however, is occupied by systematic reviews, belonging to secondary literature. They are tools aimed at
summarizing data coming from primary literature, such as RCTs, cohort and/or case-control studies.
They aim at answering a well-focused question about etiology, diagnosis, therapy and prognosis of a
certain disease, paying particular attention to the search methodology of studies to be included and
providing a critical evaluation of the resulting quality of evidence. Systematic reviews are, whenever
possible, associated with meta-analysis, which is a statistical analysis of all data coming from the
different studies included; the latter provides a quantitative analysis of findings in support or against
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a certain treatment or risk factor in the contest of a specific disease. Underlying the importance of
systematic review, the Cochrane Collaboration was founded in 1993, an international network with the
specific aim of preparing and maintaining continuously updated and publically available systematic
reviews on the impact of health interventions, which follow a unique standard of methodology.
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Figure 1. Pyramid of scientific evidence—Evidence-based medicine (EBM). In biomedical sciences, a 
pyramid represents the quality of scientific evidence; the base consists of pre-clinical research, with 
in vitro and in vivo experiments, which provides insights towards potential efficacy of a certain 
therapy. Clinical research represents a higher level of evidence, referring to in human studies; in this 
context, randomized controlled trials are methodologically the best current clinical studies. At the 
apex, updated systematic reviews and meta-analyses are considered the best available knowledge, 
suitable for clinicians to face decision-making (adapted from Varoni et al., 2015 [1]). 
In the EBM, the clinician is trained to identify the best scientific evidence currently available on 
a medical issue, after constructing an appropriate research question and using the reference database 
for medical literature (PubMed) for reviewing studies. To construct the clinical question, EBM 
proposes the PICO strategy, where P stands for Patients (with a particular condition or disease), I for 
the Intervention of interest (therapeutic, preventive, prognostic, diagnostic), C for Control or 
Comparison (the former defined as no intervention such as placebo, the latter as the standard 
intervention to be compared) and O for Outcome (the expected results coming from the intervention). 
In the phytoiatric/phytopathological area, an evidence-based approach is still missing. Similar 
to the medical sciences, the efficacy of plant protection products can be assessed with diverse 
experimental designs each with different levels of scientific evidence. In general, active substances 
are initially assayed with in vitro tests evaluating their biostatic/biocidal activity on cultivable plant 
pathogens. To the next level, in planta experiments in controlled environments, i.e. phytotron 
cabinets, growth chambers, greenhouses and screenhouses, can be carried out to test the efficacy of 
both active substances and agrochemicals on model pathosystems as well as obligate pathogens. In 
these experimental conditions, phytotoxicity and adverse effects on non-target plant species can also 
be evaluated. Overall, in vitro and in planta experiments (pre-open field studies) can be compared to 
in vitro/in vivo preclinical research of biomedical area, at the base of the evidence-based phytoiatry 
pyramid (Figure 2). Following this parallelism, multi-year open field trials, with positive (untreated) 
and negative (reference standard) controls, performed in a completely randomized design are at the 
top of the pyramid, providing the highest level of evidence on efficacy of plant protection products 
including fungicides, elicitors, plant activators, insecticides and herbicides. 
Figure 1. Pyramid of scientific evidence—Evidence-based medicine (EBM). In biomedical sciences,
a pyramid represents the quality of scientific evidence; the base consists of pre-clinical research,
with in vitro and in vivo experiments, which provides insights towards potential efficacy of a certain
therapy. Clinical research represents a higher level of evidence, referring to in human studies; in this
context, randomized controlled trials are methodologically the best current clinical studies. At the apex,
updated systematic reviews and meta-analyses are considered the best available knowledge, suitable
for clinicians to face decision-making (adapted from Varoni et al., 2015 [1]).
In the EBM, the clinician is trained to identify the best scientific evidence currently available on a
medical issue, after constructing an appropriate research question and using the reference database for
medical literature (PubMed) for reviewing studies. To construct the clinical question, EBM proposes
the PICO strategy, where P stands for Patients (with a particular condition or disease), I for the
Interve tion of interest (therapeutic, reventive, prognostic, diagnostic), C for Control or Comparison
(the former defined as no int rv ntion such as placebo, the latter as the standard intervention to be
compared) a d O for Outcome (the expected results coming from the intervention).
In the phytoiatric/phyt i l rea, an evidence-based a proach i still missing. S milar
to the medical sciences, the efficac f l t t ction products can be assessed with div rse
experimental designs each with different levels of scientific evidence. In general, active substances
are initially assayed with in vitro tests evaluating their biostatic/biocidal activity on cultivable plant
pathogens. To the next level, in planta experiments in controlled environments, i.e., phytotron cabinets,
growth chambers, greenhouses and screenhouses, can be carried out to test the efficacy of both
active substances and agrochemicals on model pathosystems as well as obligate pathogens. In these
experimental conditions, phytotoxicity and adverse effects on non-target plant species can also be
evaluated. Overall, in vitro and in planta experiments (pre-open field studies) can be compared to
in vitro/in vivo preclinical research of biomedical area, at the base of the evidence-based phytoiatry
pyramid (Figure 2). Following this parallelism, multi-year open field trials, with positive (untreated)
and negative (reference standard) controls, performed in a completely randomized design are at the
top of the pyramid, providing the highest level of evidence on efficacy of plant protection products
including fungicides, elicitors, plant activators, insecticides and herbicides.
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Figure 2. Pyramid of scientific evidence—Evidence-based phytoiatry (EBP). Suggested pyramid of 
the quality of scientific evidence in phytoiatry. In vitro and in planta experiments represent the level 
of the pre-open field research. Systematic reviews and meta-analyses need to be introduced in the 
phytoiatric/phytopathological area (‘?’ on the pyramid top). 
Of course, to design and perform an open-field trial is complex, and a number of general 
principles should be followed. First, the concept of Good Plant Protection Practice (GPP) was defined 
by the European and Mediterranean Plant Protection Organization (EPPO), a specific set of 
recommendations including guidelines on decision-making for choice of active substances and 
formulations, dosage (and appropriate volume), number of applications, timing or frequency of 
applications, equipment and method of application [2]. In addition, EPPO provides a number of 
standards covering two application fields: phytosanitary measures and plant protection products. 
Main topics include analysis of efficacy evaluation trials, efficacy evaluation of plant protection 
products (PPPs), number of efficacy trials, minimum effective dose, principles of acceptable efficacy 
and dose expression for PPPs, to name a few [3]. In addition, we have to take into account that 
legislations on PPPs are demanding, lengthy and costly, especially in the EU where issues related to 
their assessment and evaluation trials are controlled by the regulation EC 1107/2009 placed on the 
market of PPPs. During the approval process, the steps concerning the registration of new PPPs are 
declined because they require multi-year field trials to prove the efficacy of a given PPP against a 
target pest (sensu lato) under different pedo-climatic situations ruling out any negative effect on non-
target organisms. 
Not last, systematic reviews (and meta-analyses) are not used in phytoiatry/plant pathology 
research as a powerful tool to reach the highest level of evidence in a specific phytosanitary issue. 
Therefore, we believe that the plant protection sector can neither be apart from considering that 
different levels of scientific evidence actually exist nor disregard a modern evidence-based approach. 
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Figure 2. Pyramid of scientific evidence—Evidence-based phytoiatry (EBP). Suggested pyramid of
the quality of scientific evidence in phytoiatry. In vitro and in planta experiments represent the level
of the pre-open field research. Systematic reviews and meta-analyses need to be introduced in the
phytoiatric/phytopathological area (‘?’ on the pyramid top).
Of course, to design and perform an open-field trial is complex, and a number of general principles
should be followed. First, the concept of Good Plant Protection Practice (GPP) was defined by the
European and Mediterranean Plant Protection Organization (EPPO), a specific set of recommendations
including guidelines on decision-making for choice of active substances and formulations, dosage
(and appropriate volume), number of applications, timing or frequency of applications, equipment and
method of application [2]. In addition, EPPO provides a number of standards covering two application
fields: phytosanitary measures and plant protection products. Main topics include analysis of efficacy
evaluation trials, efficacy evaluation of plant protection products (PPPs), number of efficacy trials,
minimum effective dose, principles of acceptable efficacy and dose expression for PPPs, to name a
few [3]. In addition, we have to take into account that legislations on PPPs are demanding, lengthy
and costly, especially in the EU where issues related to their assessment and evaluation trials are
controlled by the regulation EC 1107/2009 placed on the market of PPPs. During the approval process,
the steps concerning the registration of new PPPs are declined because they require multi-year field
trials to prove the efficacy of a given PPP against a target pest (sensu lato) under different pedo-climatic
situations ruling out any negative effect on non-target organisms.
Not last, systematic reviews (and meta-analyses) are not used in phytoiatry/plant pathology
research as a powerful tool to reach the highest level of evidence in a specific phytosanitary issue.
Therefore, we believe that the plant protection sector can neither be apart from considering that
different levels of scientific evidence actually exist nor disregard a modern evidence-based approach.
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